Vectus Biosystems Limited
VBS.AX
Australian Securities Exchange0.12
AUD
+0.01
- -
Vectus Biosystems Limited
VBS.AX
(Australian Securities Exchange)
Recent
price
0.12
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vectus Biosystems Limited is an Australian biotechnology company engaged in the discovery and development of therapeutic treatments primarily targeting fibrosis and hypertension. The company’s core products include its lead drug candidate VB0004, which is designed to treat fibrosis and high blood pressure associated with major fibrotic diseases affecting the heart, liver, and kidneys. In addition to drug development, Vectus offers pre-clinical toxicity testing services utilizing animal and human cell models and has developed proprietary technology through its wholly-owned subsidiary Accugen Pty Limited, which enhances the speed and accuracy of DNA and RNA quantification in laboratory samples. Founded in 2011 and headquartered in Rosebery, New South Wales, Vectus Biosystems focuses its operations predominantly in Australia with research activities aligned to unmet medical needs in cardiovascular and fibrotic diseases. Recent major developments include the progression of VB0004 through various clinical trial phases, notably the completion of a phase 1a trial showing a strong safety profile, and advancement into phase 1b to further evaluate efficacy and safety. The company has raised capital through share placements and convertible note fundraising to support these clinical trials. Additionally, Vectus is advancing the commercialisation of its Accugen technology through potential direct sales, distribution partnerships, and licensing arrangements. These activities represent significant operational progress within the last two years, aimed at accelerating drug development and expanding its technology platform in the biotech sector. Vectus Biosystems remains publicly listed on the Australian Securities Exchange under the ticker VBS, continuing its strategic focus on pharmaceutical innovation and diagnostic technology development.